BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hirata T, Teshima T, Nishiyama K, Ogawa K, Otani K, Kawaguchi Y, Konishi K, Tomita Y, Takahashi H, Ohigashi H, Ishikawa O. Histopathological effects of preoperative chemoradiotherapy for pancreatic cancer: an analysis for the impact of radiation and gemcitabine doses. Radiother Oncol 2015;114:122-7. [PMID: 25614389 DOI: 10.1016/j.radonc.2015.01.004] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Chung SY, Chang JS, Lee BM, Kim KH, Lee KJ, Seong J. Dose escalation in locally advanced pancreatic cancer patients receiving chemoradiotherapy. Radiother Oncol 2017;123:438-45. [PMID: 28464997 DOI: 10.1016/j.radonc.2017.04.010] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 6.5] [Reference Citation Analysis]
2 Takahashi H, Akita H, Ioka T, Wada H, Tomokoni A, Asukai K, Ohue M, Yano M, Ishikawa O. Phase I Trial Evaluating the Safety of Preoperative Gemcitabine/nab-Paclitaxel With Concurrent Radiation Therapy for Borderline Resectable Pancreatic Cancer. Pancreas 2018;47:1135-41. [PMID: 30134354 DOI: 10.1097/MPA.0000000000001140] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 4.5] [Reference Citation Analysis]
3 Nakamura A, Prichard HA, Wo JY, Wolfgang JA, Hong TS. Elective nodal irradiation with simultaneous integrated boost stereotactic body radiotherapy for pancreatic cancer: Analyses of planning feasibility and geometrically driven DVH prediction model. J Appl Clin Med Phys 2019;20:71-83. [PMID: 30636367 DOI: 10.1002/acm2.12528] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
4 Ohira S, Isono M, Ueda Y, Hirata T, Ashida R, Takahashi H, Miyazaki M, Takashina M, Koizumi M, Teshima T. Assessment with cone-beam computed tomography of intrafractional motion and interfractional position changes of resectable and borderline resectable pancreatic tumours with implanted fiducial marker. Br J Radiol. 2017;90:20160815. [PMID: 28256908 DOI: 10.1259/bjr.20160815] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
5 Takahashi H, Yamada D, Asukai K, Wada H, Hasegawa S, Hara H, Shinno N, Ushigome H, Haraguchi N, Sugimura K, Yamamoto K, Nishimura J, Yasui M, Omori T, Miyata H, Ohue M, Yano M, Sakon M, Ishikawa O. Clinical implications of the serum CA19-9 level in "biological borderline resectability" and "biological downstaging" in the setting of preoperative chemoradiation therapy for pancreatic cancer. Pancreatology 2020;20:919-28. [PMID: 32563596 DOI: 10.1016/j.pan.2020.05.020] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
6 Ohira S, Kanayama N, Wada K, Washio H, Karino T, Ueda Y, Inui S, Miyazaki M, Koizumi M, Teshima T. A Third-Generation Adaptive Statistical Iterative Reconstruction for Contrast-Enhanced 4-Dimensional Dual-Energy Computed Tomography for Pancreatic Cancer. J Comput Assist Tomogr 2021;45:18-23. [PMID: 31738200 DOI: 10.1097/RCT.0000000000000942] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
7 Chuong MD, Frakes JM, Figura N, Hoffe SE, Shridhar R, Mellon EA, Hodul PJ, Malafa MP, Springett GM, Centeno BA. Histopathologic tumor response after induction chemotherapy and stereotactic body radiation therapy for borderline resectable pancreatic cancer. J Gastrointest Oncol 2016;7:221-7. [PMID: 27034789 DOI: 10.3978/j.issn.2078-6891.2015.075] [Cited by in F6Publishing: 11] [Reference Citation Analysis]
8 Ohira S, Wada K, Hirata T, Kanayama N, Ikawa T, Karino T, Nitta Y, Isono M, Ueda Y, Miyazaki M, Koizumi M, Teshima T. Clinical implementation of contrast-enhanced four-dimensional dual-energy computed tomography for target delineation of pancreatic cancer. Radiotherapy and Oncology 2018;129:105-11. [DOI: 10.1016/j.radonc.2018.01.012] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
9 Rowan DJ, Logunova V, Oshima K. Measured residual tumor cellularity correlates with survival in neoadjuvant treated pancreatic ductal adenocarcinomas. Annals of Diagnostic Pathology 2019;38:93-8. [DOI: 10.1016/j.anndiagpath.2018.10.013] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
10 Townend P, de Reuver PR, Chua TC, Mittal A, Clark SJ, Pavlakis N, Gill AJ, Samra JS. Histopathological tumour viability after neoadjuvant chemotherapy influences survival in resected pancreatic cancer: analysis of early outcome data. ANZ J Surg 2018;88:E167-72. [PMID: 28318082 DOI: 10.1111/ans.13897] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
11 Holyoake DLP, Robinson M, Silva M, Grose D, McIntosh D, Sebag-Montefiore D, Radhakrishna G, Mukherjee S, Hawkins MA. SPARC, a phase-I trial of pre-operative, margin intensified, stereotactic body radiation therapy for pancreatic cancer. Radiother Oncol 2021;155:278-84. [PMID: 33217498 DOI: 10.1016/j.radonc.2020.11.007] [Reference Citation Analysis]
12 Takahashi H, Akita H, Wada H, Tomokuni A, Asukai K, Takahashi Y, Yanagimoto Y, Matsunaga T, Sugimura K, Yamamoto K, Nishimura J, Yasui M, Omori T, Miyata H, Yamamoto T, Nakanishi M, Shirayanagi M, Yamasaki T, Ohue M, Yano M, Sakon M, Ishikawa O. Subclinical cancer cell dissemination in peritoneal lavage fluid detected by reverse-transcription polymerase chain reaction identifies patients at high risk for peritoneal recurrence and consequent impaired survival in the setting of preoperative chemoradiation therapy for pancreatic cancer. Surgery 2018;164:1168-77. [PMID: 30146098 DOI: 10.1016/j.surg.2018.06.047] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
13 Azab B, Macedo FI, Chang D, Ripat C, Franceschi D, Livingstone AS, Yakoub D. The Impact of Prolonged Chemotherapy to Surgery Interval and Neoadjuvant Radiotherapy on Pathological Complete Response and Overall Survival in Pancreatic Cancer Patients. Clin Med Insights Oncol 2020;14:1179554920919402. [PMID: 32669884 DOI: 10.1177/1179554920919402] [Reference Citation Analysis]
14 Cao F, Li J, Li A, Li F. Radical antegrade modular pancreatosplenectomy versus standard procedure in the treatment of left-sided pancreatic cancer: A systemic review and meta-analysis. BMC Surg 2017;17:67. [PMID: 28583142 DOI: 10.1186/s12893-017-0259-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
15 Ohira S, Yagi M, Iramina H, Karino T, Washio H, Ueda Y, Miyazaki M, Koizumi M, Teshima T. Treatment planning based on water density image generated using dual‐energy computed tomography for pancreatic cancer with contrast‐enhancing agent: Phantom and clinical study. Med Phys 2018;45:5208-17. [DOI: 10.1002/mp.13180] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
16 He J, Blair AB, Groot VP, Javed AA, Burkhart RA, Gemenetzis G, Hruban RH, Waters KM, Poling J, Zheng L, Laheru D, Herman JM, Makary MA, Weiss MJ, Cameron JL, Wolfgang CL. Is a Pathological Complete Response Following Neoadjuvant Chemoradiation Associated With Prolonged Survival in Patients With Pancreatic Cancer? Ann Surg. 2018;268:1-8. [PMID: 29334562 DOI: 10.1097/sla.0000000000002672] [Cited by in Crossref: 75] [Cited by in F6Publishing: 31] [Article Influence: 37.5] [Reference Citation Analysis]
17 N Kalimuthu S, Serra S, Dhani N, Hafezi-Bakhtiari S, Szentgyorgyi E, Vajpeyi R, Chetty R. Regression grading in neoadjuvant treated pancreatic cancer: an interobserver study. J Clin Pathol 2017;70:237-43. [PMID: 27681847 DOI: 10.1136/jclinpath-2016-203947] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
18 Holyoake DL, Robinson M, Grose D, McIntosh D, Sebag-Montefiore D, Radhakrishna G, Patel N, Partridge M, Mukherjee S, Hawkins MA. Conformity analysis to demonstrate reproducibility of target volumes for Margin-Intense Stereotactic Radiotherapy for borderline-resectable pancreatic cancer. Radiother Oncol 2016;121:86-91. [PMID: 27519585 DOI: 10.1016/j.radonc.2016.08.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]